Laboratory of Clinical Microbiology, Department of Clinical Sciences, L. Sacco Teaching Hospital, University of Milan, Via GB Grassi 74, 20157 Milan, Italy
Received 11 February 2005; returned 21 March 2005; revised 27 April 2005; accepted 24 May 2005
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods: Clinical strains of P. aeruginosa (n = 5) and Acinetobacter spp. (n = 5) susceptible to all the drugs used in the study were assayed. Development of resistance was determined by multi-step and single-step methodologies. For multi-step studies, MICs were determined after five serial passages on antibiotic-gradient plates containing each antibiotic alone or in combination with levofloxacin or ciprofloxacin. Acquisition of resistance was defined as an increase of 4-fold from the starting MIC. In single-step studies, the frequency of spontaneous mutations was calculated after a passage on plates containing antibiotics alone and in combinations at concentrations equal to the highest NCCLS breakpoints.
Results: Serial passages on medium containing single antibiotics resulted in increased MICs for each antibiotic; MIC increases were limited by antibiotics in combination. A decrease in the number of strains with MICs above the NCCLS breakpoints occurred when fluoroquinolones were combined with a second antibiotic for both P. aeruginosa and Acinetobacter spp. isolates. Frequencies of mutation were higher for antibiotics alone than for combinations.
Conclusions: Use of combinations of fluoroquinolones with ß-lactams and amikacin reduces the risk for in vitro selection of resistant P. aeruginosa and Acinetobacter spp.
Keywords: mutation frequencies , ß-lactams , fluoroquinolones
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Recommended treatments for systemic P. aeruginosa and Acinteobacter spp. infections involve combination therapy, as this increases the chance of effective initial therapy before receiving susceptibility results. Combination therapy may minimize the risk of developing resistance and has the potential for synergic activity.8 Therapy involving an aminoglycoside plus a ß-lactam with anti-pseudomonal activity has for many years represented the therapy of choice for treatment of infections caused by P. aeruginosa and related pathogens.911 However, this combination has not always been effective in preventing the emergence of resistance during therapy.12 Nowadays, anti-pseudomonal fluoroquinolones are often considered a valid alternative to aminoglycosides because of their limited nephrotoxicity and better tissue penetration, and several studies have shown in vitro synergy between ciprofloxacin or levofloxacin and anti-pseudomonal ß-lactams.1316 However, most studies on the effects of drug combinations on P. aeruginosa have investigated bactericidal and inhibitory activities by means of timekill studies, chequerboard assays or by determination of post-antibiotic effects,11,1321 and only a few have evaluated the ability of such combinations to limit development of resistance.13,22
The aim of this study was to evaluate the tendency of clinical isolates of P. aeruginosa and Acinetobacter spp. to develop phenotypic resistance to levofloxacin, ciprofloxacin, cefepime, ceftazidime, imipenem, piperacillintazobactam and amikacin after single and sequential exposures to these drugs singly or in combination (levofloxacin or ciprofloxacin with amikacin, cefepime, ceftazidime, imipenem and piperacillintazobactam).
![]() |
Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Five non-duplicate clinical isolates of P. aeruginosa and five of Acinetobacter spp. (four Acinetobacter baumannii and one Acinetobacter calcoaceticus) obtained from patients with pneumonia or septicaemia at the intensive care unit of L. Sacco Teaching Hospital, Milan, Italy were included in the study. The isolates were chosen based on their proven susceptibility to all the antibiotics evaluated in the study, as shown in Table 1.
|
Levofloxacin (Aventis Pharma Spa, Lainate, Italy), ciprofloxacin (Bayer Italia, Milan, Italy), amikacin (Sigma, St Louis, MO, USA), cefepime (Bristol Myers-Squibb, Latina, Italy), ceftazidime (GlaxoSmithKline, Verona, Italy), imipenem (Merck Sharp & Dohme, Rome, Italy) and piperacillintazobactam (Wyeth Lederle, Latina, Italy), as powders of stated potency, were used to prepare stock solutions at concentrations of 5120 mg/L as recommended by the NCCLS.23
Determination of MIC
Determination of antibiotic susceptibility was performed by the broth microdilution method according to NCCLS standards.24 NCCLS breakpoints used to define resistance were: 8 mg/L for levofloxacin,
4 mg/L for ciprofloxacin,
32 mg/L for cefepime and ceftazidime,
16 mg/L for imipenem,
128/4 mg/L for piperacillintazobactam and
64 mg/L for amikacin.
Selection of resistant bacteria (multi-step)
The ability to select resistant bacteria was evaluated by serially subculturing the chosen strains onto agar plates containing a linear gradient of the antibiotics singly or in combination, as described previously.22,25 Gradients were prepared in Petri dishes, which were poured with two layers of agar. The bottom layer consisted of MuellerHinton agar, allowed to harden with the plate slanted sufficiently to cover the entire bottom. The top layer, added to the dish in the normal position, generally contained antibiotics (alone or in combination) at concentrations of 48 x MIC. An inoculum of 109 cfu (sufficiently high to be representative of bacterial strain) was homogeneously spread on each plate, and incubated for 48 h at 37°C. Colonies growing at the highest antibiotic concentration were sampled, checked for purity, grown overnight into antibiotic-free broth, and replated on new antibiotic gradient plates. Bacteria were exposed to a maximum of five consecutive passages on the antibiotic gradients. MICs were determined after the first, the second and the fifth passage by the broth microdilution technique as described above.
Acquisition of resistance was defined as 4-fold increase in MIC with respect to the initial value, according to other authors.22
Mutational frequency (single-step)
The frequency of spontaneous single-step mutations was determined on the chosen strains by spreading 0.1 mL from a bacterial suspension of 1010 cfu/mL on antibiotic-free agar plates (after proper dilution) and on antibiotic-containing agar plates (undiluted inoculum).22 NCCLS resistance breakpoints reported in the above section were used to calculate defined antibiotic concentrations. Colonies grown after 48 h of incubation at 37°C were counted. Frequency of mutation was calculated as the number of resistant colonies per inoculum.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Results of gradient plates resistance selection for single and combined antibiotics are summarized in Tables 25, which report changes in MICs and number of strains showing increment in MICs of at least four times the initial values.
|
|
|
|
Overall, Acinetobacter showed less development of resistance than Pseudomonas. Emergence of resistance in Acinetobacter spp. appeared slower for other agents than for fluoroquinolones after two passages with single antibiotics, while, after the last passage, three strains shifted to resistant to levofloxacin and to ceftazidime, four to amikacin, cefepime and piperacillintazobactam, five to ciprofloxacin and none to imipenem (Table 4). After the last passage in the combinations, most of the acinetobacters showed a 4-fold MIC increment (Table 5). Levofloxacin was more protective than ciprofloxacin in limiting changes of susceptibility, with only one strain resistant to levofloxacin when assessed in combination with imipenem. In contrast, a total of nine strains were found to be resistant after passages in combinations with ciprofloxacin: seven were resistant to ciprofloxacin (two recovered from amikacin, cefepime and ceftazidime agar plates, and one from imipenem plates) and two were resistant to piperacillintazobactam (Table 4).
Single-step selection of resistant bacteria
The highest frequencies of mutations for antibiotics alone were found for cefepime, imipenem and piperacillintazobactam in P. aeruginosa (107) and piperacillintazobactam (
106) in Acinetobacter spp. Levofloxacin and ciprofloxacin showed a similar rate in P. aeruginosa, while a difference was found in Acinetobacter spp., where levofloxacin showed a lower frequency than ciprofloxacin (<1012 versus 109). Combinations of fluoroquinolones with ß-lactams or amikacin reduced the occurrence of mutations favouring bacterial growth to a rate of <1012, as shown in Tables 6 and 7.
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Combinations of aminoglycosides with ß-lactams represent the classical treatment for severe infections due to Gram-negative bacilli, but several studies have failed to demonstrate any benefit when combinations of aminoglycosides with ß-lactams were compared with monotherapy, whereas in another study, a decrease in pharmacodynamicpharmacokinetic parameters was observed for amikacin and imipenem when they were administered in combination compared with when they were administered separately.2931 Aminoglycoside toxicity is another factor that encourages the search for novel combinations in order to provide effective therapies.
Fluoroquinolones have proven to have a high rate of synergy with ß-lactams in in vitro evaluations, while ability to limit resistance has been rarely evaluated.1321,32
The results obtained in this study indicate the high potential of P. aeruginosa and Acinetobacter spp., although at different rates, to acquire phenotypic resistance to fluoroquinolones, ß-lactams and amikacin. The use of antibiotic combinations notably reduced the rate and the extent of MIC increase, as already reported for ciprofloxacin by other authors.22 Differences observed between mutational frequencies of levofloxacin and ciprofloxacin in Acinetobacter and between P. aeruginosa and Acinetobacter strains confirmed that the propensity of fluoroquinolones to select resistance varies regarding the agent concerned, its antibiotic concentrations relative to the MIC and the microorganisms involved, as shown in other studies.22,33,34
In the same way, differences observed among combinations are suggestive of differences in the ability of ß-lactams to select resistance. Therefore, the choice of antibiotics involved in combination should take this into account, in addition to antimicrobial activity in terms of synergy shown by antibiotics themselves.
Recent studies have identified use of fluoroquinolones as a risk factor for infection or colonization resulting from multidrug-resistant P. aeruginosa and A. baumannii, while in another study, use of fluoroquinolones in combinations and longer duration of therapy have been independently associated with emergence of multidrug resistance.3537 However, these studies are small and to date, no large-scale prospective randomized clinical trials have specifically evaluated the relationship between fluoroquinolone use and the emergence of resistance during monotherapy and combination therapy.
Determination of whether in vitro results obtained in this study may correlate with clinical efficacy remains difficult, since, even in in vitro pharmacokinetic models that allow treatment of bacteria with the same pharmacokinetically changing concentrations of antibiotic occurring in vivo, many factors involved in the host, such as immunity, are absent. A recent in vitro pharmacokinetic study on emergence of resistance in P. aeruginosa, simulating treatment with a combination of levofloxacin plus imipenem, demonstrated superiority of combinations over antibiotics alone in limiting the emergence of resistance.32 These data contrast with those obtained in the present study, where resistance to imipenem also developed in the combinations. The different experimental models employed in the two studies are likely to be responsible for this difference.
The principal aim of this study was to compare the abilities of ciprofloxacin and levofloxacin alone and in combinations with other antibiotics to select phenotypic resistance, without any molecular characterization of the resistant isolates. However, it is well known that mutations or overexpression of specific efflux pumps are essential mechanisms of P. aeruginosa resistance to several antibiotics. Topoisomerase mutations that confer higher levels of resistance seem to be a secondary event in resistance to fluoroquinolones, and chromosomal and plasmid-carried ß-lactamase concurred in resistance to ß-lactams.14,38,39 In Acinetobacter spp., gyrA and parC mutations and upregulation of the adeB efflux pump seem to be the major factors responsible for the development of multidrug resistance.40,41 Any hypothesis on the mechanisms in our strains is rather difficult, and all of the above-mentioned mechanisms (particularly efflux pumps) could be involved, as suggested by others.32
Although our study has several limitations, such as the limited number of strains and passages evaluated, and the absence of molecular typing of resistant isolates, results indicate that use of fluoroquinolones in combination with ß-lactams or amikacin may limit the decrease of susceptibility and development of resistance in P. aeruginosa and Acinetobacter spp. during therapy. However, further studies, including kinetic evaluations, are needed to better investigate the issue.
![]() |
Acknowledgements |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2.
Okamoto K, Gotoh N, Nishino T. Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 26969.
3. Poole K, Krebes K, McNally C et al. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 1993; 175: 736372.[Abstract]
4.
Masuda N, Sakagawa E, Ohya S et al. Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 22426.
5. Hilf M, Yu VL, Sharp J et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 5406.[ISI][Medline]
6. Vidal F, Mensa J, Almela M et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Arch Intern Med 1996; 156: 21216.[Abstract]
7. Carmeli Y, Troillet N, Karchmer AW et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Int Med 1999; 159: 112732.[CrossRef][ISI]
8. Burgess D. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005; 40: S99104.[CrossRef][ISI][Medline]
9. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement. Am J Resp Crit Care Med 1996; 153: 171125.[ISI][Medline]
10. Allan JD, Moellering RC. Management of infections caused by Gram-negative bacilli: the role of antimicrobial combinations. Rev Infect Dis 1985; 7: 55971.
11. den Hollander JG, Horrevorts AM, van Goor ML et al. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1997; 41: 95100.[Abstract]
12. Sanders CC, Sanders WE Jr. ß-lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15: 82439.[ISI][Medline]
13. Burgess DS, Nathisuwan S. Piperacillin/tazobactam, cefepime, gentamicin, ciprofloxacin and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002; 44: 3541.[CrossRef][ISI][Medline]
14.
Visalli MA, Jacobs MR, Appelbaum PC. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, ceftazidime, meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and timekill methodology. Antimicrob Agents Chemother 1998; 42: 9535.
15. Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2003; 46: 1317.[CrossRef][ISI][Medline]
16. Song W, Woo HJ, Kim JS et al. In vitro activity of ß-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003; 21: 812.[CrossRef][ISI][Medline]
17. Critchley IA, Sahm DF, Kelly LJ et al. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli. Chemotherapy 2003; 49: 448.[CrossRef][ISI][Medline]
18. Pendland SL, Messick CR, Jung R. In vitro synergy testing of levofloxacin, ofloxacin and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002; 42: 758.[CrossRef][ISI][Medline]
19. Erdem I, Kaynar-Tascioglu J, Kaya B et al. The comparison of the in vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Int J Antimicrob Agents 2002; 20: 3846.[CrossRef][ISI][Medline]
20. Hostacka A. Comparison of postantibiotic effects of imipenem and netilmicin alone and in combination against Pseudomonas aeruginosa. Arzneim Forsch 1997; 47: 9657.[ISI][Medline]
21. Sood P, Mandal A, Mishra B. Postantibiotic effect of a combination of antimicrobial agents on Pseudomonas aeruginosa. Chemotherapy 2000; 46: 1736.[CrossRef][ISI][Medline]
22. Michéa Hamzehpour M, Kahr A, Pechère JC. In vitro stepwise selection of resistance to quinolones, ß-lactams and amikacin in nosocomial Gram-negative bacilli. Infection 1994; 22 (Suppl. 2): S10510.[CrossRef][ISI][Medline]
23. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement M100-S11. NCCLS, Villanova, PA, USA, 2001.
24. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A5. NCCLS, Villanova, PA, USA, 2000.
25. Bryson L, Szybalski W. Microbial selection. Science 1952; 116: 4551.[ISI]
26.
Kang CI, Kim SH, Park WB et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49: 7606.
27.
Jain R, Danziger LH. Multidrug resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004; 38: 144959.
28. Eliopoulos GM, Eliopoulos CT. Antibiotic combinations: should they be tested? Clin Microbiol Rev 1988; 1: 13956.[Medline]
29. Cometta A, Baumgartner JD, Lew D et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38: 130913.[Abstract]
30. Bernabeu-Wittel M, Pichardo C, García-Curiel A et al. Pharmacokinetic/pharmacodynamic assessment of the in vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005; 11: 31925.[CrossRef][ISI][Medline]
31. Hooker KD, DiPiro JT, Wynn JJ. Aminoglycoside combinations versus beta-lactams alone for penetrating abdominal trauma: a meta-analysis. J Trauma 1991; 31: 115560.[ISI][Medline]
32. Lister PD, Wolter DJ. Levofloxacinimipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis 2005; 40: S10514.[ISI][Medline]
33.
Gilbert DN, Kohlheep SJ, Slama KA et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin levofloxacin, and trovafloxacin. Antimicrob Agents Chemother 2001; 45: 88392.
34. Gillespie T, Masterton RG. Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients. Int J Antimicrob Agents 2002; 19: 37782.[CrossRef][ISI][Medline]
35. Paramythiotou E, Lucet JC, Timsit JF et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004; 38: 6707.[CrossRef][ISI][Medline]
36.
Villers D, Espaze E, Coste-Burel M et al. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med 1998; 129: 1829.
37. Nseir S, Di Pompeo C, Soubrier S et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005; 33: 2839.[CrossRef][ISI][Medline]
38.
Llanes C, Hocquet D, Vogne C et al. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother 2004; 48: 1797802.
39. Van Loon HJ, Box AT, Verhoef J et al. Evaluation of genetic determinants involved in beta-lactam- and multiresistance in a surgical ICU. Int J Antimicrob Agents 2004; 24: 1304.[CrossRef][ISI][Medline]
40.
Higgins PG, Wisplinghoff H, Stefanik D et al. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 2004; 54: 8213.
41. Van Looveren M, Goossens H, ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684704.[CrossRef][ISI][Medline]
|